Actas dermo-sifiliograficas最新文献

{"title":"Bariatric Stamp","authors":"L. Taboada Paz, E. Vicente Basanta, M.M. Otero Rivas","doi":"10.1016/j.ad.2025.104511","DOIUrl":"10.1016/j.ad.2025.104511","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 2","pages":"Article 104511"},"PeriodicalIF":2.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progressive Verrucous Plaques of the Face","authors":"L. Becker Micheletto , M. Ceolin Vione , J. Peruzzo","doi":"10.1016/j.ad.2025.104509","DOIUrl":"10.1016/j.ad.2025.104509","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 2","pages":"Article 104509"},"PeriodicalIF":2.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semi-Buried Dermogaleal Subcutaneous Suture: How to Keep Tension Away From the Wound","authors":"A. Bennassar Vicens","doi":"10.1016/j.ad.2025.104521","DOIUrl":"10.1016/j.ad.2025.104521","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 2","pages":"Article 104521"},"PeriodicalIF":2.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of a Novel Heterozygous Variant c.497g>a (p.gly166glu) in Exon 5 of the Sting1 Gene as the Causative Factor of Sting-Associated Vasculopathy With Onset in Infancy (SAVI): A Case Report","authors":"M. Mansilla-Polo , D. Martín-Torregrosa , M. Saro-Buendía , B. Escutia-Muñoz , R. Botella-Estrada","doi":"10.1016/j.ad.2025.104512","DOIUrl":"10.1016/j.ad.2025.104512","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 2","pages":"Article 104512"},"PeriodicalIF":2.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Nonacral Cutaneous Lentiginous Melanomas According to the Degree of Solar Elastosis: Support for the New World Health Organization Classification","authors":"R. Moro ,&nbsp;F. Mayo-Martínez ,&nbsp;Z. García-Casado ,&nbsp;M. Aguerralde-Martin ,&nbsp;Victor Traves ,&nbsp;E. Manrique-Silva ,&nbsp;C. Requena ,&nbsp;D.E. Elder ,&nbsp;E. Nagore","doi":"10.1016/j.ad.2025.104519","DOIUrl":"10.1016/j.ad.2025.104519","url":null,"abstract":"<div><h3>Background and aims</h3><div>The new WHO classification distinguishes two main pathogenic pathways for cutaneous melanoma, low and high-chronic sun damage (CSD). However, there are no studies to support its validity in the category of non-acral cutaneous lentiginous melanoma (NACLM). Thus, the aim of this study was to correlate the degree of solar elastosis (SE) with a range of clinicopathologic and genomic parameters in a cohort of NACLMs.</div></div><div><h3>Material and methods</h3><div>We conducted a retrospective cohort study of patients affected by an in situ or invasive NACLM distributed across three groups depending on the grade of SE. NACLM includes lentigo maligna melanoma and lentigo maligna, and other non-acral cutaneous lesions with a lentiginous growth pattern.</div></div><div><h3>Results</h3><div>The study included a total of 257 patients, 132 men (51.4%) and 125 women (48.6%) with a median age of 71 years. SE grade I was reported in 38 cases (14.8%), grade II in 61 cases (23.7%), and grade III in 158 cases (61.5%). Higher SE grade was related to head/neck location, older age at diagnosis and presence of lentigines in melanoma area. Lower SE grade was related to other locations, higher nevi count, presence of regression and BRAF V600E mutation (univariate logistic regression quantification: V600E vs WT; OR, 0.23; 95%CI, 0.05–1.06; <em>p</em> <!-->=<!--> <!-->0.059).</div></div><div><h3>Conclusion</h3><div>SE grade is useful to classify NACLMs in different groups distinguished by their clinical, pathological, and molecular features. These results endorse the new WHO classification of low- and high-CSD melanomas. Moreover, they highlight the importance of reporting the grade of SE in the pathological report.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 2","pages":"Article 104519"},"PeriodicalIF":2.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of Basosquamous Carcinoma With Sonidegib in a Patient with HIV","authors":"C. Fernández Romero ,&nbsp;L. Vila Cobreros ,&nbsp;P. Navarro Conde ,&nbsp;E. Gimeno Carpio","doi":"10.1016/j.ad.2025.104508","DOIUrl":"10.1016/j.ad.2025.104508","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 2","pages":"Article 104508"},"PeriodicalIF":2.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Systematic Review of Treatments for Cutaneous Chronic Graft-versus-Host Disease","authors":"M. Zhou ,&nbsp;M. Mansilla-Polo ,&nbsp;P. Fernandez-Peñas","doi":"10.1016/j.ad.2025.104522","DOIUrl":"10.1016/j.ad.2025.104522","url":null,"abstract":"<div><div>Chronic graft-versus-host disease (cGVHD) is a major multiple organ complication of allogeneic hematopoietic stem cell transplantation, and skin involvement is associated with substantial mortality, morbidity and reduction in quality of life. However, more than half of patients are refractory to current first-line therapy and there is still a lack of high-level evidence regarding alternative therapeutic agents. This systematic review was conducted by two independent reviewers who searched and screened records published from database inception to May 2024 in PubMed, Embase, and the Cochrane Central Register of Controlled Trials, using prespecified inclusion and exclusion criteria aligned with the study objective. Two reviewers assessed the risk of bias and quality of evidence of trials eligible for review. Seven randomized controlled trials of extracorporeal photopheresis (ECP) with standard therapy, imatinib, entospletinib with prednisone, ruxolitinib, and ibrutinib with prednisone were eligible for inclusion. Ruxolitinib demonstrated superiority versus standard therapy and placebo with an overall response rate of 41.5% and a reduction in body surface area affected from 14.5% down to 6.2%. No other treatments conferred a statistically significant benefit versus standard therapy or placebo. Entospletinib was markedly inferior to placebo. Although all 7 trials demonstrated some risk of bias, they were found to have a moderate-to-high quality of evidence. In conclusion, of all therapeutic agents reviewed, only ruxolitinib demonstrated high-level evidence of a modest efficacy in treating cutaneous cGVHD and should be considered as a line of therapy in addition to current first-line therapy. Further high-level studies are needed to identify alternative therapeutic agents and validate their efficacy profile.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 2","pages":"Article 104522"},"PeriodicalIF":2.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postauthorization Safety Study (NISSO) Assessing the Long-Term Safety Profile of Sonidegib in Patients With Locally Advanced Basal Cell Carcinoma: Interim Analysis From the Spanish Cohort","authors":"S. Beà Ardébol ,&nbsp;G.M. Pérez-Pastor ,&nbsp;R. Fernández-de-Misa ,&nbsp;R. Botella-Estrada ,&nbsp;V. Ruiz-Salas ,&nbsp;Á. Flórez ,&nbsp;M. Mayor Arenal ,&nbsp;M.J. Fuente González ,&nbsp;P. Bassas-Freixas ,&nbsp;A. Toll ,&nbsp;P. Valerón Almazán ,&nbsp;R. Arntz ,&nbsp;J. Malvehy","doi":"10.1016/j.ad.2025.104524","DOIUrl":"10.1016/j.ad.2025.104524","url":null,"abstract":"<div><h3>Background</h3><div>This study aims to present an interim analysis of safety data from the Spanish cohort of the NISSO post-authorization safety study on the long-term tolerability of sonidegib in patients with locally advanced basal cell carcinoma (laBCC).</div></div><div><h3>Methods</h3><div>NISSO is a non-interventional, multinational, post-authorization safety study (<span><span>NCT04066504</span><svg><path></path></svg></span>). Patients with laBCC were administered sonidegib 200<!--> <!-->mg/day and monitored for 3 years. Dose adjustments were permitted according to the Spanish prescribing information.</div></div><div><h3>Results</h3><div>Between January 8th, 2021, and March 7th, 2022, a total of 51 patients with laBCC were enrolled in the study in Spain (data cut June 22nd, 2023). Treatment was discontinued in 39 patients (76.5%), primarily due to treatment success (<em>n</em> <!-->=<!--> <!-->11, 21.6%), patient or guardian decision (<em>n</em> <!-->=<!--> <!-->8, 15.7%), and physician decision (<em>n</em> <!-->=<!--> <!-->8, 15.7%). The median duration of exposure was 6.5 months (IQR, 5.69–11.91 months). A total of 45 (88.2%) patients experienced at least one treatment-emergent adverse event (TEAE). The most common TEAEs were muscle spasms (<em>n</em> <!-->=<!--> <!-->23, 45.1%), alopecia (<em>n</em> <!-->=<!--> <!-->23, 45.1%), and dysgeusia (<em>n</em> <!-->=<!--> <!-->23, 45.1%). Cumulative rates of the above-mentioned TEAEs at 3 months were 27.5%, 11.8%, and 29.4%, respectively. Most TEAEs were grade<!--> <!-->≤<!--> <!-->2. TEAEs led to treatment discontinuation in 10 patients (19.6%), while 8 (15.7%) required dose modifications due to adverse events. Serious drug-related TEAEs were reported in 2 patients (3.9%).</div></div><div><h3>Conclusions</h3><div>Most patients experienced grade<!--> <!-->≤<!--> <!-->2 common TEAEs, such as muscle spasms, dysgeusia, and alopecia that mostly manifested 3 months into therapy. These interim results confirm the safety profile observed in the BOLT study, demonstrating that sonidegib is well-tolerated in a real-world setting in Spain.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 2","pages":"Article 104524"},"PeriodicalIF":2.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and Survival of Cutaneous Squamous Cell Carcinoma: A Spanish Multicenter Population-Based Study","authors":"N.F. Fernández-Martínez ,&nbsp;D. Redondo-Sánchez ,&nbsp;A. Ameijide ,&nbsp;M. Carulla ,&nbsp;J. Rubió-Casadevall ,&nbsp;R. Marcos-Gragera ,&nbsp;M. Guevara ,&nbsp;A. Gasque ,&nbsp;I. García-Doval ,&nbsp;S. Arias-Santiago ,&nbsp;J. Galceran ,&nbsp;M.J. Sánchez","doi":"10.1016/j.ad.2025.104490","DOIUrl":"10.1016/j.ad.2025.104490","url":null,"abstract":"<div><h3>Background</h3><div>Cutaneous squamous cell carcinoma (cSCC) constitutes a serious public health problem, as it is the 2nd most frequent skin cancer. Few studies have assessed epidemiological indicators of cSCC in Southern Europe. The objectives of this study were to analyze its incidence rate and estimate survival of cSCC cases from all Spanish population-based cancer registries that register this cancer.</div></div><div><h3>Materials and methods</h3><div>We conducted a retrospective descriptive study of all incident first cSCC cases registered in Girona, Granada, Navarre and Tarragona (Spain) from 1994 to 2017. Crude and age-standardized (ASR-E) incidence rates were calculated. Incidence trends were analyzed using joinpoint regression. Observed survival was estimated using the Kaplan–Meier method and relative survival was estimated using the Ederer II method.</div></div><div><h3>Results</h3><div>A total of 22,434 cSCC cases (61.5% men) were registered, accounting for 20.3% of all skin cancers. The most common anatomical site was the skin of face, scalp and neck (59.1%) and the incidence rate increased exponentially with age. The annual ASR-E per 100,000 inhabitants was 25.0 in women and 56.6 in men. Both sexes showed a significant upward incidence trend, with an annual percent change of +2.0% (95%CI, +1.6% to +2.4%). The 5-year relative survival rate was 93.5% (95%CI, 92.5–94.6%), slightly higher in women, and did not seem to increase over time.</div></div><div><h3>Conclusions</h3><div>This study provides an updated description of cSCC incidence and survival, which are key indicators to frame the scenario of this cancer in Spain. Overall, results are consistent with former studies, showing a rising trend in the incidence rate alongside high survival rates. Further research is warranted to elucidate the causes underlying these findings.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 1","pages":"Article 104490"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older","authors":"S. Vañó-Galván ,&nbsp;I. Figueras-Nart ,&nbsp;C. Serrano ,&nbsp;M.P. Fortes ,&nbsp;V. Herrera-Lasso ,&nbsp;R. Botella-Estrada","doi":"10.1016/j.ad.2025.104487","DOIUrl":"10.1016/j.ad.2025.104487","url":null,"abstract":"<div><div>Alopecia areata (AA) is a dermatological disease of immune origin characterized by partial or total hair loss of the scalp (<em>alopecia totalis</em>) or the whole body (<em>alopecia universalis</em>). Current therapeutic options, both topical and systemic, use nonspecific immunosuppressive or immunomodulatory management strategies. The crucial role of Janus kinases (JAK) in the pathogenesis of the disease has led to a change in the therapeutic landscape, opening new approaches in the management of this disease. Ritlecitinib, a JAK3/TEC kinase inhibitor, has recently been approved for the treatment of severe AA in patients aged 12 and older. This review analyses the mechanism of action of ritlecitinib and the evidence for its safety and efficacy profile in patients with severe AA.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 1","pages":"Article 104487"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}